Intravenous Immune Globulin

Covers IVIG for listed FDA‑approved indications (e.g., primary humoral immunodeficiencies, ITP, CIDP, MMN, Kawasaki, etc.) and specified compendial off‑label uses; non‑compendial/unlisted off‑label uses are not covered. Key requirements include documented diagnosis with indication‑specific criteria (e.g., pretreatment low IgG or impaired antibody response and/or recurrent infections; specific thresholds such as IgG <600 mg/dL for CLL/hematologic indications and <400 mg/dL for pediatric HIV), prescription/consultation by an appropriate specialist, required prior therapy trials where noted, adherence to dosing/timing/approval‑duration limits, and demonstration of clinical benefit for reauthorization.

"Immunotherapy-related toxicities associated with checkpoint inhibitor therapy"

Sign up to see full coverage criteria, indications, and limitations.